Cat Scans Confirm Rimonabant (Acomplia) Reduces Da (go back »)

Cat (CT) scans of adipose patients advised with Acomplia (rimonabant) accept accepted for the aboriginal time that the diet biologic decidedly reduces the alarming blazon of belly blubber that generally leads to blazon 2 diabetes, according to researchers.

In a late-breaking address presented at the anniversary affair of the European Atherosclerosis Society in Istanbul, the advisers said cat scans showed that rimonabant analysis for a year resulted in decidedly greater reductions in belly fat than a placebo and aswell helped abate the blubbery alarmist index.

The after-effects came from the ADAGIO-LIPIDS analytic trial, a abstraction conducted in 799 patients with belly blubber and with the top triglyceride - low HDL-cholesterol dyslipidemia. Dyslipidemia is a action that contributes to the development of atherosclerosis (commonly alleged hardening of the arteries).

The purpose of the study, according to advance researcher Dr Jean-Pierre Després of Université Laval in Quebec City, was to actuate the aftereffect of rimonabant on HDL (good) cholesterol and triglyceride levels and on the cardiometabolic contour of overweight/obese patients with dyslipidemia.

Patients advised for a year with rimonabant, Després reported, saw their HDL cholesterol added by an boilerplate 9.7% while triglycerides were bargain 15.5%. Blood burden was bargain 3.3 mm Hg, and deepening levels abstinent by C-reactive protein (CRP) were aswell reduced.

But for the aboriginal time in a rimonabant trial, patients were aswell accustomed cat scans to admeasurement how abundant subcutaneous and belly fat was absent on rimonabant as able-bodied as to actuate whether rimonabant could abate alarmist fat.

"Although we had affirmation from the appearance III studies conducted with rimonabant that (the drug) could abet a abridgement in waist ambit (a awkward brand of belly fat) and advance several appearance of the metabolic syndrome, no abstraction had anytime quantified the aftereffect of this biologic on belly adiposity and alarmist fat," Després said.

The advisers appear that rimonabant analysis for a year bargain belly adipose tissue by an boilerplate 10.1%, which was greater than the 5.1 percent accident of subcutaneous fat, and produced a "significant: abatement in the blubbery alarmist index.

"Results of ADAGIO-LIPIDS accommodate abutment to the angle that patients with belly blubber who are generally either dyslipidemic or with blazon 2 diabetes (or both) represent a accordant subpopulation of overweight/obese patients who would decidedly account from rimonabant therapy," the advisers concluded.